Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $3.7 million.

  • Niagen Bioscience's Cash from Operations rose 563.66% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 41276.65%. This contributed to the annual value of $12.1 million for FY2024, which is 7014.19% up from last year.
  • Per Niagen Bioscience's latest filing, its Cash from Operations stood at $3.7 million for Q3 2025, which was up 563.66% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Cash from Operations ranged from a high of $8.6 million in Q4 2024 and a low of -$7.9 million during Q2 2021
  • Over the past 5 years, Niagen Bioscience's median Cash from Operations value was $295000.0 (recorded in 2024), while the average stood at -$379473.7.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 2257272.73% in 2021, then surged by 257796.61% in 2025.
  • Over the past 5 years, Niagen Bioscience's Cash from Operations (Quarter) stood at -$4.9 million in 2021, then surged by 93.37% to -$328000.0 in 2022, then skyrocketed by 297.87% to $649000.0 in 2023, then skyrocketed by 1222.5% to $8.6 million in 2024, then crashed by 56.98% to $3.7 million in 2025.
  • Its Cash from Operations stands at $3.7 million for Q3 2025, versus $1.2 million for Q2 2025 and $7.9 million for Q1 2025.